CARM · As filed with the SEC
Carisma Therapeutics cash flow statement, by fiscal year
The statement as Carisma Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
Consolidated Statements of Cash Flows · USD thousands
| USD thousands | FY2024 Year ended Dec 31, 2024 | FY2023 Year ended Dec 31, 2023 | FY2022 Year ended Dec 31, 2022 | FY2021 Year ended Dec 31, 2021 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net loss | — | (86,879) | — | — |
| Net loss | (60,477) | — | (19,884) | (336) |
| Adjustment to reconcile net loss to net cash used in operating activities: | ||||
| Depreciation and amortization expense | 3,354 | 2,837 | 13 | 85 |
| Loss on disposal of property and equipment | 0 | 159 | — | — |
| Stock-based compensation expense | 3,649 | 2,316 | 6,909 | 5,143 |
| Change in fair value of contingent consideration | — | — | (52,000) | (56,840) |
| Intangibles impairment charge | — | — | 27,764 | 31,700 |
| Net amortization of discounts and premiums on marketable securities | — | — | (913) | — |
| Reduction in the operating right of use assets | 4,963 | 5,428 | — | — |
| Amortization of debt discount | 0 | 1,283 | — | — |
| Change in fair value of derivative liability | 0 | 84 | — | — |
| Accretion on marketable securities | 0 | (709) | — | — |
| Write-off of property and equipment | 362 | — | — | — |
| Realized gain on marketable securities | 0 | (399) | — | — |
| Non-cash interest expense | 217 | 139 | — | — |
| Loss on sale of equipment | 49 | — | — | — |
| Gain on sale of sale-leaseback | (82) | — | — | — |
| Changes in operating assets and liabilities: | ||||
| Accounts receivable (net) | — | — | 21,010 | (24,493) |
| Other receivables | — | — | 2,658 | — |
| Prepaid expenses and other assets | (3,120) | 1,046 | 18,076 | (17,964) |
| Long term prepaid expenses | — | — | 7,192 | — |
| Other assets | — | — | 123 | — |
| Accounts payable | (1,852) | 2,191 | (1,620) | (249) |
| Accrued expenses | (213) | (2,899) | 17,067 | (4,424) |
| Deferred revenue | (1,434) | (1,046) | (1,500) | (1,500) |
| Operating lease liabilities | (5,525) | (4,941) | — | — |
| Other long term liabilities | 192 | 213 | — | — |
| Net cash used in operating activities | (59,917) | (81,177) | 24,895 | (68,878) |
| Purchase of marketable securities | — | — | (128,999) | — |
| Proceeds from maturity of marketable securities | — | — | 75,000 | — |
| Disposal of equipment | — | — | 30 | — |
| Cash flows from investing activities: | ||||
| Purchase of marketable securities | 0 | (34,460) | — | — |
| Proceeds from the sale of marketable securities | 0 | 108,000 | — | — |
| Purchases of property and equipment | (123) | (1,132) | — | (4) |
| Net cash (used in) provided by investing activities | (123) | 72,408 | (53,969) | (4) |
| Proceeds from issuance of common stock and common stock warrants, net of issuance costs | — | — | — | 0 |
| Cash flows from financing activities: | ||||
| Cash, cash equivalents and restricted cash acquired in connection with the reverse recapitalization | 0 | 37,903 | — | — |
| Payment of reverse recapitalization finance costs | 0 | (5,814) | — | — |
| Proceeds from the issuance of common stock in pre-closing financing | 0 | 30,640 | — | — |
| Payment of principal related to finance lease liabilities | (1,429) | (1,301) | — | — |
| Proceeds from failed sale-leaseback arrangement | 686 | 1,183 | — | — |
| Payment of finance liability from failed sale-leaseback arrangements | (1,309) | (1,069) | — | — |
| Payment of deferred financing costs | 0 | (146) | — | — |
| Proceeds from issuance of convertible promissory note | — | 0 | — | — |
| Proceeds from the exercise of stock options | 4 | 187 | 1 | 42 |
| Proceeds from exercises of common stock warrants | — | — | 0 | 1,126 |
| Proceeds from sale of common stock pursuant to ESPP | — | — | 0 | 0 |
| Sale of common stock under Open Market Sales Agreement, net of issuance costs | 2,392 | 597 | 0 | 174,962 |
| Net cash provided by financing activities | 344 | 62,180 | 1 | 176,129 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | — | — | (29,073) | 107,247 |
| Net (decrease) increase in cash and cash equivalents | (59,696) | 53,411 | — | — |
| Cash and cash equivalents at beginning of the year | 77,605 | 24,194 | 162,656 | 55,409 |
| Cash and cash equivalents at end of the year | 17,909 | 77,605 | 133,583 | 162,656 |
| Supplemental disclosures of cash flow information: | ||||
| Right-of-use assets related to the adoption of ASC 842 | — | — | — | 0 |
| Cash paid for interest | 192 | 352 | — | — |
| Supplemental disclosure of non-cash financing and investing activities: | ||||
| Cash paid for amounts included in the measurement of lease liabilities | — | — | 127 | 174 |
| Conversion of convertible preferred stock and non-controlling interests upon Merger | 0 | 122,204 | — | — |
| Conversion of convertible promissory note, accrued interest and derivative liability upon Merger | 0 | 42,447 | — | — |
| Unrealized gain on marketable securities | 0 | 41 | — | — |
| Deferred financing costs in accrued expenses | — | 0 | — | — |
| Reclassification of deferred financing costs to additional paid-in-capital | 9 | — | — | — |
| Right-of-use assets obtained in exchange for new financing lease liabilities | 1,660 | 0 | — | — |
| Allocation of debt proceeds to derivative liability | — | 0 | — | — |
| Right-of-use assets obtained in exchange for new operating lease liabilities | 6,411 | 2,779 | 0 | 0 |
| Deemed Dividend on adjustment of exercise price on certain warrants | — | — | 0 | 0 |
| Modification of operating lease right-of-use asset and operating lease liabilities | (1,581) | — | — | — |
| Disposal of property and equipment in exchange for reduction in financing lease liability | 396 | — | — | — |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.